<DOC>
	<DOCNO>NCT01179594</DOCNO>
	<brief_summary>This randomize , 2 x 2 factorial , parrallel group study compare efficacy safety 48 versus 96 week peginterferon alfa-2a [ Pegasys ] , without entecavir , patient HbeAg negative chronic hepatitis B . Patients randomly allocate receive Pegasys ( 180mcg subcutaneously weekly ) 48 week plus placebo ( group A ) entecavir ( 0,5mg orally daily , group B ) week 12-36 , Pegasys ( 180mcg subcutaneously weekly ) 96 week plus placebo ( group C ) entecavir ( group D ) week 12-36 . Anticipated time study treatment 48 96 week , follow-up 48 week . Target sample size &lt; 500 patient .</brief_summary>
	<brief_title>A Study 48 Versus 96 Weeks Peginterferon Alfa-2a Pegasys Treatment , With Without Entecavir , Patients With Chronic Hepatitis B .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>adult patient , &gt; /= 18 year age chronic hepatitis B &gt; /= 6 month HBeAg negative screening adequate renal function antiviral therapy chronic hepatitis B within previous 6 month hepatitis A , C , D HIV infection treatment systemic acyclovir famciclovir within previous 6 month decompensated liver disease ( Childs BC ) history evidence medical condition associate chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>